Enrolled HCC patients met the inclusion criterion, in the late or advanced stage, without extrahepatic metastasis and macro-vascular invasion (secondary vascular branches or below it), and the number of tumor was≤3.Eligible participants will be randomly assigned to receive either TACE or TACE+EBRT.